Literature DB >> 23151449

Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.

Shixia Wang1, Michael Kishko, Shengqin Wan, Yan Wang, Frank Brewster, Glenda E Gray, Avye Violari, John L Sullivan, Mohan Somasundaran, Katherine Luzuriaga, Shan Lu.   

Abstract

Recent studies have reported that founder viruses play unique roles in establishing HIV-1 infection. Understanding the biological and immunological features of envelope glycoproteins (Env) from such viruses may facilitate the development of effective vaccines against HIV-1. In this report, we evaluated the immunogenicity of gp120 immunogens from two pairs of clade B and two pairs of clade C mother-to-child transmitted (MTCT) HIV-1 variants that had various levels of sensitivity to broadly neutralizing monoclonal antibodies. Individual gp120 DNA and protein vaccines were produced from each of the eight MTCT Env antigens included in the current study. Rabbits were immunized with these gp120 immunogens by the DNA prime-protein boost approach. High level Env-specific antibody responses were elicited by all MTCT gp120 immunogens. However, their abilities to elicit neutralizing antibody (NAb) responses differed and those from relatively neutralization-resistant variants tended to be more effective in eliciting broader NAb. Results of this pilot study indicated that not all MTCT Env proteins have the same potential to elicit NAb. Understanding the mechanism(s) behind such variation may provide useful information in formulating the next generation of HIV vaccines.

Entities:  

Keywords:  DNA-protein boost vaccination; HIV-1; antibody; immunogenicity; mother-to-child transmission

Mesh:

Substances:

Year:  2012        PMID: 23151449      PMCID: PMC3601138          DOI: 10.4161/hv.22414

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  38 in total

1.  Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Authors:  F Gao; S G Morrison; D L Robertson; C L Thornton; S Craig; G Karlsson; J Sodroski; M Morgado; B Galvao-Castro; H von Briesen; S Beddows; J Weber; P M Sharp; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

2.  Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.

Authors:  Michael Vaine; Maria Duenas-Decamp; Paul Peters; Qin Liu; James Arthos; Shixia Wang; Paul Clapham; Shan Lu
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

3.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

4.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

5.  Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission.

Authors:  N Ahmad; B M Baroudy; R C Baker; C Chappey
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.

Authors:  Shixia Wang; Jeffrey S Kennedy; Kim West; David C Montefiori; Scott Coley; John Lawrence; Siyuan Shen; Sharone Green; Alan L Rothman; Francis A Ennis; James Arthos; Ranajit Pal; Phillip Markham; Shan Lu
Journal:  Vaccine       Date:  2008-07-23       Impact factor: 3.641

7.  Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing.

Authors:  Jesus F Salazar-Gonzalez; Elizabeth Bailes; Kimmy T Pham; Maria G Salazar; M Brad Guffey; Brandon F Keele; Cynthia A Derdeyn; Paul Farmer; Eric Hunter; Susan Allen; Olivier Manigart; Joseph Mulenga; Jeffrey A Anderson; Ronald Swanstrom; Barton F Haynes; Gayathri S Athreya; Bette T M Korber; Paul M Sharp; George M Shaw; Beatrice H Hahn
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

8.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.

Authors:  Elin Solomonovna Gray; Tammy Meyers; Glenda Gray; David Charles Montefiori; Lynn Morris
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.

Authors:  Paul J Peters; Maria J Duenas-Decamp; W Matthew Sullivan; Richard Brown; Chiambah Ankghuambom; Katherine Luzuriaga; James Robinson; Dennis R Burton; Jeanne Bell; Peter Simmonds; Jonathan Ball; Paul R Clapham
Journal:  Retrovirology       Date:  2008-01-18       Impact factor: 4.602

View more
  1 in total

Review 1.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.